Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lee M. Katrincic is active.

Publication


Featured researches published by Lee M. Katrincic.


Journal of Pharmaceutical Sciences | 2008

Enantiotropically-related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid: Crystal structures and multinuclear solid-state NMR

Frederick G. Vogt; Lee M. Katrincic; Stacey T. Long; Ronald L. Mueller; Robert A. Carlton; Yan T. Sun; Matthew N. Johnson; Royston C. B. Copley; Mark E. Light

Single crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), and solid-state NMR (SSNMR) techniques are used to analyze the structures of two nonsolvated polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid. These polymorphs are enantiotropically-related with a thermodynamic transition temperature of 35 +/- 3 degrees C. The crystal structure of Form 1, which is thermodynamically more stable at lower temperatures, was determined by SCXRD. The crystal structure of Form 2 was determined using PXRD structure solution methods that were assisted using two types of SSNMR experiments, dipolar connectivity experiments and chemical shift measurements. These experiments determined certain aspects of local conformation and intermolecular packing in Form 2 in comparison to Form 1, and provided qualitative knowledge that assisted in obtaining the best possible powder structure solution from the X-ray data. NMR chemical shifts for 1H, 13C, 15N, and 19F nuclei in Forms 1 and 2 are sensitive to hydrogen-bonding behavior, molecular conformation, and aromatic pi-stacking interactions. Density functional theory (DFT) geometry optimizations were used in tandem with Rietveld refinement and NMR chemical shielding calculations to improve and verify the Form 2 structure. The energy balance of the system and other properties relevant to drug development are predicted and discussed.


International Journal of Pharmaceutics | 2009

Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system.

Lee M. Katrincic; Yan T. Sun; Robert A. Carlton; Ann M. Diederich; Ronald L. Mueller; Frederick G. Vogt

Solid-state characterization methods are used to study a dimorphic pharmaceutical compound and select a form for development. Polymorph screening found that [4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl] acetic acid can crystallize into two non-solvated polymorphs designated Forms 1 and 2. Physical methods including vibrational spectroscopy, X-ray powder diffraction, solid-state NMR (SSNMR), thermal analysis, and gravimetric water vapor sorption are used to fully characterize the two polymorphs. Temperature-dependent competitive ripening experiments and solubility measurements indicated that the polymorphs in this system exhibit enantiotropy with a thermodynamic transition temperature of 35+/-3 degrees C. This complicates the selection of a polymorph to progress in drug development. Both forms had undesirable qualities; however, a particular drawback of Form 1 was found in its tendency to convert to Form 2 upon milling. Combining this effect and the desired formulation approach with physical property results led to a rationale for the choice of Form 2 for further development. Because this form is thermodynamically metastable at room temperature, analytical approaches were developed to ensure its exclusive presence, including a quantitative infrared spectroscopic method for drug substance and (13)C and (19)F solid-state NMR limit tests for the undesired form in drug product at drug loads of 8.3% (w/w).


Crystal Growth & Design | 2006

Physical, crystallographic, and spectroscopic characterization of a crystalline pharmaceutical hydrate : Understanding the role of water

Frederick G. Vogt; Jeffrey Brum; Lee M. Katrincic; Agnes Flach; Jerome M. Socha; Richard M. Goodman; R. Curtis Haltiwanger


Archive | 2004

Carvedilol salts, corresponding compositions, methods of delivery and/or treatment

Christopher S. Brook; Pingyun Y. Chen; Wei Chen; Qunying Dai; Philip C. Dell'orco; Clifford S. Labaw; Ann Marie Diederich; Choon K Oh; Claire Hisler; David H. Igo; Lee M. Katrincic; Li-Jen Ping; Paul G. Spoors; Jun Wang; Christopher Werner


Archive | 2005

Compounds which increase apolipoprotein a-1 production and uses thereof in medicine

Pingyun Chen; Alain Claude-Marie Daugan; Romain Luc Marie Gosmini; David H. Igo; Lee M. Katrincic; Paul Martres; Edwige Nicodeme; Daniel Patience


Crystal Growth & Design | 2014

Crystallization and Solid-State Characterization of the Hemihydrate of Albuterol Hemisulfate

Joanna A. Bis; Paul D. Boyle; Stephen Aaron Relayo Carino; David H. Igo; Lee M. Katrincic


Archive | 2013

Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or treatment methods

Christopher S. Brook; クリストファー・エス・ブルック; Wei Chen; チェン・ウェイ; Philip C. Dell'orco; フィリップ・シー・デロルコ; Lee M. Katrincic; リー・エム・カトリンシック; Ann Marie Louvet; アン・マリー・ルーベット; Choon K Oh; チョン・ケイ・オー; Paul G. Spoors; ポール・ジー・スプーアズ; Christopher Werner; クリストファー・ワーナー


Archive | 2010

Carvedilol phosphate salt and/or solvate thereof, corresponding composition, and/or method of treatment

Christopher S. Brook; Wei Chen; Philip C. Dell'orco; Lee M. Katrincic; Ann Marie Louvet; Choon K Oh; Paul G. Spoors; Christopher Werner; アン・マリー・ルーベット; クリストファー・エス・ブルック; クリストファー・ワーナー; チェン・ウェイ; チョン・ケイ・オー; フィリップ・シー・デロルコ; ポール・ジー・スプーアズ; リー・エム・カトリンシック


Archive | 2004

Carvedilol-salze, entsprechende zusammensetzungen, verfahren zur abgabe und/oder behandlung

Christopher S. Brook; Pingyun Y. Chen; Wei Chen; Qunying Dai; Philip C. Dell'orco; Claire Hisler; David H. Igo; Lee M. Katrincic; Clifford S. Labaw; Ann Marie Louvet; Choon K Oh; Li-Jen Ping; Paul G. Spoors; Jun Wang; Christopher Werner


Archive | 2004

Sels de carvedilol, compositions correspondantes, procedes d'administration et/ou de traitement

Christopher S. Brook; Pingyun Y. Chen; Wei Chen; Qunying Dai; Philip C. Dell'orco; Claire Hisler; David H. Igo; Lee M. Katrincic; Clifford S. Labaw; Ann Marie Louvet; Choon K Oh; Li-Jen Ping; Paul G. Spoors; Jun Wang; Christopher Werner

Collaboration


Dive into the Lee M. Katrincic's collaboration.

Top Co-Authors

Avatar

David H. Igo

Catalent Pharma Solutions

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jun Wang

Chinese Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joanna A. Bis

University of South Florida

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge